Latest California Healthline Stories
But Americans generally have little confidence that the White House or Congress will recommend the right thing, a new poll shows.
Despite big 2020 campaign promises to deliver lower costs on prescription drugs, Democrats have failed to unite around a legislative plan.
The condition can be an early signal of Alzheimer’s disease, but not always. Other health concerns could be causing thinking or memory problems, and the new drug, Aduhelm, would not be appropriate for those patients.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
At least three promising antiviral treatments for covid-19 are being tested in clinical trials, with results expected as soon as late fall or winter.
Los medicamentos que se están investigando tendrían el potencial de interferir con la capacidad del virus para replicarse en las células humanas.
Congress is back in session with a short time to finish a long to-do list, including keeping the government operating and paying its bills. Hanging in the balance is President Joe Biden’s entire domestic agenda, including major changes proposed for Medicare, Medicaid and the Affordable Care Act. Meanwhile, the new Texas abortion law that bans the procedure early in pregnancy is prompting action in Washington. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews former FDA Commissioner Scott Gottlieb about his new book on the covid-19 pandemic.
Biologic drugs, made from living organisms, and the cheaper biosimilar drugs that mimic them are more complex than chemical drugs and their generic counterparts. The Food and Drug Administration says biosimilars are as safe and effective as the biologics, and doctors agree — but they are cautious about changing the treatment regimen of patients doing well.
The Food and Drug Administration has been mired in controversies related to drug approvals and covid vaccines, all without a permanent leader.
The House oversight committee is requesting conflict-of-interest disclosure forms from a National Academies committee studying organ transplants. KHN previously reported on apparent conflicts among members of a committee studying drug waste.